Gene Arrays

genearrays.com

Welcome to the “Gene Arrays” Genome and Microarray facilities. Our arrays carried out at certified labs in New York, NY, USA. Gene Arrays specialized in the area of genome sequencing using various instruments (Illumina HiSeq 2500, Illumina MiSeq, Ion Torrent and Pacific Biosciences) and microarrays carried out Affymetrix and Illumina platforms and also Library preparation for NGS including miRNA extractions. Bioinformatic Support: NGS data analysis, ChIP-Seq, RNA-Seq, DNA methylation, Microarray analysis for Gene Expression Profiling (GEP), and Pathway analysis

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

INTRON CONFIRMS EFFICACY OF CDL200 AGAINST CDI CLINICAL ISOLATES

iNtRON Biotechnology | July 12, 2022

news image

iNtRON Biotechnology announced that CDL200, a novel biological drug candidate under the development of the world's first enteric colon-targeted capsule formulation for the treatment of intractable and recurrent CDI confirmed the strong efficacy against clinical isolates from CDI patients. A company official explained that the antibacterial activity of CDL200 was evaluated for 20 clinical isolates from patients in Europe and Korea, and rapid lysis effect within few minutes afte...

Read More

Cell and Gene Therapy

KITE AND SHORELINE BIOSCIENCES FORM STRATEGIC PARTNERSHIP TO DEVELOP NOVEL ALLOGENEIC CELL THERAPIES

Kite, Shoreline Biosciences | June 18, 2021

news image

Kite, a Gilead Company, and Shoreline Biosciences, Inc., a biotechnology firm developing intelligently designed allogeneic off-the-shelf, standardized, and targeted natural killer (NK) and Macrophage cellular immunotherapies achieved from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, announced a strategic partnership today to develop novel cell therapies across a variety of indications. The collaboration will combine Shoreline’s profound experi...

Read More

Industrial Impact

GLUBIO COMPLETES SERIES A+ FINANCING OF $22 MILLION TO ADVANCE THE DEVELOPMENT OF NOVEL TPD DRUGS

GluBio Therapeutics Inc | August 02, 2022

news image

GluBio Therapeutics, a biotech company focused on developing novel targeted protein degradation (TPD) drugs, recently announced the completion of Series A+ financing of $22 million. This round is led by Qiming Venture Partners and joined by Lilly Asia Ventures and Kaitai Capital, bringing the total capital raised to nearly $90 million since its establishment in March, 2021. The investment will help advance two molecular glue degraders with best-in-class potential into the clinic f...

Read More

Cell and Gene Therapy

BONE THERAPEUTICS AND LINK HEALTH SIGN A NON-BINDING TERM SHEET FOR THE GLOBAL RIGHTS OF ALLOB

Bone Therapeutics | November 29, 2021

news image

BONE THERAPEUTICS the cell therapy company addressing unmet medical needs in orthopedics and other diseases, and Link Health Pharma Co., Ltd announce the signing of a non-binding term sheet for the global rights for ALLOB, Bone Therapeutics’ allogeneic bone cell therapy. Subject to the fulfillment of customary condition precedents, Bone Therapeutics and Link Health aim to complete the final agreement and to fully execute it by the end of 2021. This new partnership is s...

Read More
news image

Industrial Impact

INTRON CONFIRMS EFFICACY OF CDL200 AGAINST CDI CLINICAL ISOLATES

iNtRON Biotechnology | July 12, 2022

iNtRON Biotechnology announced that CDL200, a novel biological drug candidate under the development of the world's first enteric colon-targeted capsule formulation for the treatment of intractable and recurrent CDI confirmed the strong efficacy against clinical isolates from CDI patients. A company official explained that the antibacterial activity of CDL200 was evaluated for 20 clinical isolates from patients in Europe and Korea, and rapid lysis effect within few minutes afte...

Read More
news image

Cell and Gene Therapy

KITE AND SHORELINE BIOSCIENCES FORM STRATEGIC PARTNERSHIP TO DEVELOP NOVEL ALLOGENEIC CELL THERAPIES

Kite, Shoreline Biosciences | June 18, 2021

Kite, a Gilead Company, and Shoreline Biosciences, Inc., a biotechnology firm developing intelligently designed allogeneic off-the-shelf, standardized, and targeted natural killer (NK) and Macrophage cellular immunotherapies achieved from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, announced a strategic partnership today to develop novel cell therapies across a variety of indications. The collaboration will combine Shoreline’s profound experi...

Read More
news image

Industrial Impact

GLUBIO COMPLETES SERIES A+ FINANCING OF $22 MILLION TO ADVANCE THE DEVELOPMENT OF NOVEL TPD DRUGS

GluBio Therapeutics Inc | August 02, 2022

GluBio Therapeutics, a biotech company focused on developing novel targeted protein degradation (TPD) drugs, recently announced the completion of Series A+ financing of $22 million. This round is led by Qiming Venture Partners and joined by Lilly Asia Ventures and Kaitai Capital, bringing the total capital raised to nearly $90 million since its establishment in March, 2021. The investment will help advance two molecular glue degraders with best-in-class potential into the clinic f...

Read More
news image

Cell and Gene Therapy

BONE THERAPEUTICS AND LINK HEALTH SIGN A NON-BINDING TERM SHEET FOR THE GLOBAL RIGHTS OF ALLOB

Bone Therapeutics | November 29, 2021

BONE THERAPEUTICS the cell therapy company addressing unmet medical needs in orthopedics and other diseases, and Link Health Pharma Co., Ltd announce the signing of a non-binding term sheet for the global rights for ALLOB, Bone Therapeutics’ allogeneic bone cell therapy. Subject to the fulfillment of customary condition precedents, Bone Therapeutics and Link Health aim to complete the final agreement and to fully execute it by the end of 2021. This new partnership is s...

Read More